Clinical Trial Update: Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study [Phase 2]

View source ↗

Summary

Phase 2 feasibility study evaluating a sodium-glucose cotransporter-2 (SGLT2) inhibitor for acute cardiorenal syndrome; the trial is currently active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiorenal Syndrome

Drugs mentioned

• SGLT2 inhibitor (unspecified) (SGLT2 inhibitor)

Snippet

Sponsor: Yale University | Conditions: Cardiorenal Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING